Clinical Trial Update: DESTINY Breast Respond HER2-low Europe

View source ↗

Summary

Clinical trial update announcing recruitment in Europe for the DESTINY Breast Respond HER2-low study evaluating trastuzumab deruxtecan in unresectable or metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Conditions: Unresectable Breast Cancer, Metastatic Breast Cancer | Status: RECRUITING